Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.1.7 (acetylcholinesterase)
 28,390 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Urinary incontinence can have a significant impact on patients' quality of life. Some causes involve physiologic and structural disorders of the urinary system. Other causes do not directly affect the urinary system but are related to difficulties in reacting to the urge to urinate or getting to the toilet alone, or an increase in urine output. Toxic substances or drugs are sometimes implicated. Drugs that affect one or more of the components of the normal continence mechanism expose patients to the risk of urinary incontinence. Some of these drugs act on the urinary system, particularly the autonomic nervous system; some increase urine output; some impair physical or cognitive function; and others cause urinary retention, leading to overflow incontinence. Drugs known to cause urinary incontinence are often prescribed for older patients, who are already at increased risk: sedatives, neuroleptics, antidepressants, cholinesterase inhibitors used in Alzheimer's disease, diuretics, alpha blockers used in hypertension or benign prostatic hyperplasia, and menopausal hormone replacement therapy.
 ...
PMID:Drug-induced urinary incontinence. 2624 Aug 82

Rivastigmine is a non-competitive reversible inhibitor of acetylcholinesterase which is approved as one of the fi rst-line treatment options for Alzheimer's disease. We present the case of a 33-year-old woman with acute cholinergic syndrome secondary to deliberate rivastigmine poisoning. The patient presented at the emergency department (ED) with drowsy consciousness, dizziness, vomiting, diarrhea, sweating, and hypertension (171/103 mmHg). At the scene, an empty bottle of Rivast 120 mL/Bot, containing rivastigmine 2 mg/mL, was found beside the patient. Two hours later, we noted bronchorrhea and persistent salivation along with drowsiness, agitation, fatigue, incontinence, and limbs paralysis. A notably low serum cholinesterase level (651 U/l) was identified. Acute cholinergic syndrome secondary to rivastigmine intoxication was diagnosed. Endotracheal intubation with ventilator support was required due to respiratory failure. Atropine (0.5 mg intravenous injection) was administered. She was subsequently admitted to the intensive care unit for further care. Extubation was performed on the third day. The patient insisted on being discharged on the second day after extubation, and after administration of a total of 11 mg of atropine, no signs of either intermediate syndrome or delayed polyneuropathywere noted. rivastigmine, an acetylcholinesterase inhibitor, can precipitate an acute cholinergic crisis in cases of intoxication. Typical clinical features of cholinergic excess include increased secretions in the airway and oral cavity, miosis, diarrhea, anxiety, twitching, bronchoconstriction, convulsions, confusion, and gastrointestinal and muscular cramps. The treatment for acute cholinergic crisis is administration of atropine alone or in combination with an antidote to the cholinesterase inhibitor (such as pralidoxime). Patients often recover well with atropine supplements and optimal supportive care.
 ...
PMID:Successful Resuscitation of a Young Girl Who Drank Rivastigmine With Respiratory Failure. 3299 49


<< Previous 1 2